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the genetic test resulted in an incremental cost-effective-
ness ratio was $32,633 per QALY gained. Sensitivity
analysis produced results ranging from increased costs of
$300,430 and 3.6 additional cases of severe periodontitis
(per one thousand patients) to cost savings of $830,140
and 52.8 fewer cases of severe periodontitis. Sources of
uncertainty were 1) patient compliance based on test re-
sult, 2) effectiveness of non-surgical therapy, and 3) the
relative risk for progression based on genotype. CON-
CLUSION: The use of genetic testing to guide treatment
for periodontitis may result in a wide range of outcomes
under different modeling scenarios. These results range
from improved patient health and cost-savings to addi-
tional costs and poorer health. Economic modeling has
identified the additional data required to determine if IL-1
testing can be implemented in a primary care setting in a
cost-effective manner. These methods may be used by the
health insurance industry to assess the cost-effectiveness
of genetic testing for predisposition towards other dis-
eases.
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OBJECTIVE: This study investigates the incremental cost
of dry eye disease (keratitis sicca) in a managed care pop-
ulation. METHODS: Patients with dry eye diagnoses
(ICD-9-CM  370.33, 375.15, 710.2) or punctal occlu-
sion procedures (CPT-4  68760, 68761) during 1997–
1998 were identified from PharMetrics’ Integrated Out-
comes database of 7 million patients. Controls were ran-
domly selected and matched 1:1 to dry eye cases on age
category, gender and managed care plan. Costs were cal-
culated for 6 months before and after the first dry eye-
related claim for cases, or the midpoint of claims history
for controls. RESULTS: The prevalence of dry eye dis-
ease was 0.48% in 1997 and 0.39% in 1998. Dry eye pa-
tients (n  31,683) were more likely than controls to use
ophthalmic medications, many of which are not indicated
for dry eye (P  .001). Use of non-ophthalmic medications
was similar between cohorts. Total charges rose $454.79
(22.2%) for dry eye patients, significantly more than for
controls ($289.48 [15.9%]) (P  .001). This was mostly
due to a rise in outpatient charges ($257.40 [28.7%] for
cases versus $76.14 [11.2%] for controls). Dry eye diag-
noses/procedures were associated with greater increases
in outpatient charges, pharmacy charges, and total medi-
cal charges (P  .0001). Dry eye patients experienced a
greater average increase in total medical costs than did con-
trols, mostly arising from outpatient charges. CONCLU-
SION: We conclude that a major factor in dry eye-related
cost increases is additional physician visits, which may be
a consequence of the ineffectiveness of available therapies.
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OBJECTIVE: The objective of our work was to translate
the PDI into French, with careful attention to the linguis-
tic aspects and the cultural context of the French patients.
CONTEXT: The PDI is a scale devised by Prof. A. Finlay
of Cardiff to evaluate the impact of psoriasis on the life
of the patient. This questionnaire has been used in nu-
merous studies to evaluate the consequences of the dis-
ease in daily life or the effects of different treatments. RE-
SULTS: With the author’s approval, the questionnaire
was translated from English to French by two indepen-
dent translators. The two versions were compared and a
few non significant differences were noted. A third trans-
lation from English to French was realized with the assis-
tance of the APLCP, psoriasis patient support group.
When compared to the first two, this third translation
brought out the specificity of the French cultural context
and the reality of the disease. To make sure that the
translation was consistent with our objective, the ques-
tionnaire was sent to five patients and translated from
French to English by two independent translators. For a
large-scale validation, this questionnaire was sent by post
to 5000 psoriasis patients belonging to the APLCP. With
the addition of a questionnaire on the patient’s behavior
in respect to the treatment, “Living With Psoriasis” will
make it possible to evaluate every two years the impact
and the daily consequences of psoriasis on French pa-
tients and thus become a decision support tool. CON-
CLUSION: The novelty of this initiative resides in the in-
volvement of a patient support group at every step on a
level rarely attained, not only in the translation but also
in the validation of the questionnaire. This close involve-
ment reflects the key role of a patient support group in
the management of the disease.
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OBJECTIVES: To examine physician prescribing pattern
of antibiotics for otitis media in children and compare
them with therapeutic guidelines issued by the American
Academy of Pediatrics, Family Physicians, and Otolaryn-
gology, for appropriateness. Also, to calculate the cost
savings that could be achieved by adhering to the guide-
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lines. METHODS: Data from the National Ambulatory
Medical Care Survey (NAMCS) 1997 was utilized. Pa-
tients with principal diagnosis of otitis media with age
less than or equal to 12 years were analyzed using multi-
ple linear and binomial logit regression models. Appro-
priate antibiotics are defined as those that are recom-
mended by the guidelines. The average wholesale price of
recommended antibiotics was compared with the inap-
propriate antibiotics prescribed. The dosage of antibiot-
ics was confirmed by the IMS health and the advice of a
practicing Otolaryngologist. Antibiotics cost was calcu-
lated by using the Red Book 1997 and 1998. The
weighted average method was used to calculate the aver-
age wholesale price of the various quantity packages and
dosage forms. This study utilized the methodology of re-
lating a secondary database to an outside source (Red
Book) to calculate the cost. RESULTS: The average cost
of a course of appropriate antibiotic (penicillin and its de-
rivatives) was found to be $8.07, compared to $69.56 for
expensive antibiotics (difference  $61.49). Children less
than four years of age were prescribed more expensive
antibiotics (R2  0.287). Pediatricians, and Otolaryngol-
ogists prescribed appropriate and less expensive antibiot-
ics than other family physicians (R2  0.144). There was
no relationship between the physician’s specialty and pa-
tient’s age for inappropriate antibiotics prescribing (R2 
0.345). CONCLUSIONS: Adhering to the guidelines and
prescribing of appropriate antibiotics appears to save
cost. Inappropriate prescribing of antibiotics for otitis
media should be addressed more explicitly in general
practice.
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INTRODUCTION: Healing after a burn injury requires
a temporary wound cover until the skin epithelium heals.
Traditional wound covering, human cadaver allograft
(HCA), is expensive, and limited by availability. OBJEC-
TIVE: To determine if artificial skin substitute (Tran-
scyte) wound cover is cost-effective for temporary wound
coverage in patients with major total body surface
(TBSA) burns. METHODS: Incremental cost per quality
adjusted life year (QALY) in 2000 US dollars is estimated
assuming a base case adult patient who has 40% TBSA
burn with no inhalation injury, complications, or facial
burn followed for one year after HCA or Transcyte pro-
cedure. A societal perspective is used. Utilities were sur-
veyed from burn-unit hospital employees. Other vari-
ables are taken from literature. RESULTS: Under the
base case, Transcyte saves $3600 over HCA, and adds
0.04 QALYs. Quality of life was significantly greater in
the Transcyte group (0.54, 95% CI  0.48–0.59) vs.
HCA group (0.65, 95% CI  0.57–0.74, p  0.04) while
in the hospital, but not significantly different while recov-
ering at home, after recovery, and at work. The incre-
mental QALY of Transcyte minus HCA must be 0.07
in order for the ICER to reach a threshold of $50,000.
Sensitivity analysis shows that a 33% increase in Tran-
scyte price will reach the threshold ICER of $50,000. In
addition, this model is highly sensitive to utility at work;
a 22% decrease of at-work utility with Transcyte will re-
sult in an ICER greater than $50,000. CONCLUSIONS:
The results show that use of Transcyte as a temporary
wound covering for 40% TBSA burns is a dominant
strategy relative to standard HCA. Use of this artificial
skin results in cost savings, due to faster healing and less
operation room time. A gain in QALYs is seen with
Transcyte, due to less scarring and pain during the heal-
ing process.
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OBJECTIVE: To compare the total, drug, and medical
care costs of common practice and best practice manage-
ment of primary open-angle glaucoma (POAG). METH-
ODS: A Delphi panel of ophthalmologists specialized in
glaucoma management was convened in order to delin-
eate practice patterns representative of community physi-
cians (common practice), and to characterize the ideal or
optimal standards of care (best practice). A decision ana-
lytic approach was used to depict and economically
quantify the clinical sequelae under each scenario for
POAG patients initiated on medical therapy. Common
and best practice decision trees were developed for proto-
typic agents of the most commonly used first-line classes
of medications. Percentage likelihood of drug usage was
determined based upon physician consensus whereas
drug and surgical efficacy rates were determined based
upon a composite of published data. Typical drug dosing
regimens and number of medical visits, as determined by
physician consensus, were used to estimate the cost of
treatment. RESULTS: The total average annual cost of
treatment per eye was estimated at $733.85 for common
practice and $732.09 for best practice. Drug costs were
estimated at $358.66 for common practice and $341.38
for best practice. Costs of medical care were estimated at
$375.19 for common practice and $390.71 for best prac-
tice. Surgical costs comprised a larger proportion of med-
ical care costs in best practice as compared to common
practice (17.84% vs. 14.29%). In comparing best prac-
tice and common practice decision analyses, non-selective
beta-blockers were used less often whereas alpha-2 ago-
